Literature DB >> 34419824

Symptomatic and asymptomatic peripheral artery disease and the risk of abdominal aortic aneurysm: The Atherosclerosis Risk in Communities (ARIC) study.

Caitlin W Hicks1, Ada Al-Qunaibet2, Ning Ding3, Lucia Kwak3, Aaron R Folsom4, Hirofumi Tanaka5, Thomas Mosley6, Lynne E Wagenknecht7, Weihong Tang4, Gerardo Heiss8, Kunihiro Matsushita9.   

Abstract

BACKGROUND AND AIMS: Symptomatic peripheral artery disease (PAD) is a risk factor for abdominal aortic aneurysm (AAA). However, data on the association of asymptomatic PAD with AAA are limited. We explored the association of symptomatic and asymptomatic PAD with AAA.
METHODS: We primarily assessed a prospective association of symptomatic (based on clinical history) and asymptomatic (ankle-brachial index ≤0.9) PAD at baseline (1987-89 [ages 45-64 years]) with incident AAA in a biracial community-based cohort, the Atherosclerosis Risk in Communities Study. We secondarily investigated a cross-sectional association of PAD with ultrasound-based AAA (diameter≥3.0 cm) (2011-13 [ages 67-91 years]).
RESULTS: Of 14,148 participants (55.1% female, 25.5% black, 0.9% with symptomatic PAD) in our prospective analysis (median follow-up 22.5 years), 530 (3.7%) developed incident AAA. Symptomatic PAD had a higher hazard ratio (HR) of incident AAA [4.91 (95%CI 2.88-8.37)], as did asymptomatic PAD with ABI≤0.9 [2.33 (1.55-3.51)], compared to the reference ABI>1.1-1.2 in demographically-adjusted models. Crude 15-year cumulative incidence of AAA in these three groups were 12.3%, 3.9%, and 1.5%, respectively. The associations remained significant after accounting for other potential confounders [corresponding HR 2.96 (95%CI 1.73-5.07) and 1.52 (95%CI 1.00-2.30), respectively]. The cross-sectional analysis demonstrated similar patterns with ultrasound-based AAA [odds ratio 2.46 (95%CI 1.26-4.81) for symptomatic PAD and 3.98 (1.96-8.08) for asymptomatic PAD in a demographically-adjusted model].
CONCLUSIONS: Our prospective and cross-sectional data show elevated risk of AAA in both symptomatic and asymptomatic PAD. Our data support the current recommendation of AAA screening in symptomatic PAD patients and suggest the potential extension to asymptomatic PAD patients as well.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Abdominal aortic aneurysm; Asymptomatic; Peripheral artery disease; Screening; Symptomatic

Mesh:

Year:  2021        PMID: 34419824      PMCID: PMC8440445          DOI: 10.1016/j.atherosclerosis.2021.08.016

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   6.847


  24 in total

1.  A new device for automatic measurements of arterial stiffness and ankle-brachial index.

Authors:  Miriam Y Cortez-Cooper; James A Supak; Hirofumi Tanaka
Journal:  Am J Cardiol       Date:  2003-06-15       Impact factor: 2.778

2.  Detection of abdominal aortic aneurysm in patients with peripheral artery disease.

Authors:  A Barba; L Estallo; L Rodríguez; M Baquer; M Vega de Céniga
Journal:  Eur J Vasc Endovasc Surg       Date:  2005-06-15       Impact factor: 7.069

3.  Screening for abdominal aortic aneurysm: U.S. Preventive Services Task Force recommendation statement.

Authors:  Michael L LeFevre
Journal:  Ann Intern Med       Date:  2014-08-19       Impact factor: 25.391

4.  The prevalence of asymptomatic and symptomatic peripheral arterial disease and peripheral arterial disease risk factors in the U.S. population.

Authors:  Judith Aponte
Journal:  Holist Nurs Pract       Date:  2011 May-Jun       Impact factor: 1.000

Review 5.  2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Marie D Gerhard-Herman; Heather L Gornik; Coletta Barrett; Neal R Barshes; Matthew A Corriere; Douglas E Drachman; Lee A Fleisher; Francis Gerry R Fowkes; Naomi M Hamburg; Scott Kinlay; Robert Lookstein; Sanjay Misra; Leila Mureebe; Jeffrey W Olin; Rajan A G Patel; Judith G Regensteiner; Andres Schanzer; Mehdi H Shishehbor; Kerry J Stewart; Diane Treat-Jacobson; M Eileen Walsh
Journal:  J Am Coll Cardiol       Date:  2017-03-21       Impact factor: 24.094

6.  The Society for Vascular Surgery practice guidelines on the care of patients with an abdominal aortic aneurysm.

Authors:  Elliot L Chaikof; Ronald L Dalman; Mark K Eskandari; Benjamin M Jackson; W Anthony Lee; M Ashraf Mansour; Tara M Mastracci; Matthew Mell; M Hassan Murad; Louis L Nguyen; Gustavo S Oderich; Madhukar S Patel; Marc L Schermerhorn; Benjamin W Starnes
Journal:  J Vasc Surg       Date:  2018-01       Impact factor: 4.268

7.  Circulating Biomarkers and Abdominal Aortic Aneurysm Incidence: The Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  Aaron R Folsom; Lu Yao; Alvaro Alonso; Pamela L Lutsey; Emil Missov; Frank A Lederle; Christie M Ballantyne; Weihong Tang
Journal:  Circulation       Date:  2015-06-17       Impact factor: 29.690

8.  Prevalence and associations of abdominal aortic aneurysm detected through screening. Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Group.

Authors:  F A Lederle; G R Johnson; S E Wilson; E P Chute; F N Littooy; D Bandyk; W C Krupski; G W Barone; C W Acher; D J Ballard
Journal:  Ann Intern Med       Date:  1997-03-15       Impact factor: 25.391

9.  The reliability of the ankle-brachial index in the Atherosclerosis Risk in Communities (ARIC) study and the NHLBI Family Heart Study (FHS).

Authors:  Beth D Weatherley; Lloyd E Chambless; Gerardo Heiss; Diane J Catellier; Curtis R Ellison
Journal:  BMC Cardiovasc Disord       Date:  2006-02-21       Impact factor: 2.298

10.  Associations of Obesity With Incident Hospitalization Related to Peripheral Artery Disease and Critical Limb Ischemia in the ARIC Study.

Authors:  Caitlin W Hicks; Chao Yang; Chiadi E Ndumele; Aaron R Folsom; Gerardo Heiss; James H Black; Elizabeth Selvin; Kunihiro Matsushita
Journal:  J Am Heart Assoc       Date:  2018-08-21       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.